Beclabuvir

• CAT Number: I005682
• CAS Number: 958002-33-0
• Molecular Formula: C36H45N5O5S
• Molecular Weight: 659.84
• Purity: ≥95%
• Target: NS5B
• Solubility: DMSO: ≥ 30 mg/mL
• Storage: Store at -20°C
• IC50: < 28 nM (NS5B protein)

Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC50 of < 28 nM. 


In Vitro: Beclabuvir demonstrates additive or synergistic antiviral activity with pegIFN/RBV and in 2- or 3-drug combinations with a range of DAAs, such as HCV NS3 protease inhibitors, NS5A inhibitors/’ and/or nucleoside NS5B inhibitors[2]. 


In Vivo: The combination of beclabuvir with asunaprevir and daclatasvir achieves very high rates of viral eradication (about 90%) in patients infected with HCV genotype 1, which is the most common genotype worldwide[1].

Reference

[1]. Gentile I, et al. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs. 2015;24(8):1111-21. 





[2]. Tatum H, et al. A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. J Viral Hepat. 2015 Aug;22(8):658-64. 





[3]. Muir AJ, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 5;313(17):1736-44.